X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2130) 2130
Book Review (757) 757
Publication (120) 120
Book Chapter (8) 8
Conference Proceeding (5) 5
Magazine Article (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1885) 1885
humans (1851) 1851
diabetes mellitus, type 2 - drug therapy (1381) 1381
dipeptidyl-peptidase iv inhibitors - therapeutic use (1088) 1088
male (904) 904
hypoglycemic agents - therapeutic use (849) 849
type 2 diabetes (847) 847
female (766) 766
dipeptidyl-peptidase iv inhibitors - adverse effects (731) 731
endocrinology & metabolism (711) 711
middle aged (657) 657
diabetes (631) 631
hypoglycemic agents - adverse effects (553) 553
aged (531) 531
animals (483) 483
treatment outcome (483) 483
glucagon-like peptide-1 (462) 462
pharmacology & pharmacy (452) 452
sitagliptin (434) 434
diabetes mellitus, type 2 - blood (412) 412
adamantane - analogs & derivatives (387) 387
adult (380) 380
double-blind (380) 380
glucose (375) 375
metformin (364) 364
dipeptidyl-peptidase iv inhibitors - administration & dosage (359) 359
hypoglycemic agents (353) 353
dipeptidyl-peptidase iv inhibitors - pharmacology (347) 347
glycemic control (347) 347
dipeptidyl peptidase-4 inhibitor (343) 343
drug therapy, combination (330) 330
hypoglycemic agents - administration & dosage (318) 318
risk factors (309) 309
blood glucose - drug effects (302) 302
blood glucose - metabolism (296) 296
insulin (280) 280
diabetes mellitus (274) 274
vildagliptin (269) 269
care and treatment (267) 267
dipeptidyl peptidase 4 - metabolism (262) 262
safety (259) 259
analysis (258) 258
metformin - therapeutic use (255) 255
sitagliptin phosphate (253) 253
adamantane - therapeutic use (248) 248
type 2 diabetes mellitus (248) 248
drug therapy (247) 247
type-2 diabetes-mellitus (246) 246
diabetes therapy (238) 238
glycated hemoglobin a - metabolism (235) 235
diabetes mellitus, type 2 - complications (234) 234
double-blind method (233) 233
dipeptidyl peptidase-4 inhibitors (224) 224
efficacy (224) 224
beta-cell function (220) 220
internal medicine (219) 219
hypoglycemic agents - pharmacology (213) 213
medicine, general & internal (212) 212
adamantane - adverse effects (201) 201
research (201) 201
dpp-4 inhibitor (200) 200
improves glycemic control (195) 195
dextrose (193) 193
clinical trials (191) 191
hypoglycemia - chemically induced (188) 188
linagliptin (186) 186
abridged index medicus (178) 178
mellitus (175) 175
therapy (175) 175
hypoglycemia (172) 172
glucagon (170) 170
triazoles - therapeutic use (169) 169
pyrazines - therapeutic use (168) 168
risk (165) 165
sulfonylurea compounds - therapeutic use (161) 161
diabetes mellitus, type 2 - metabolism (160) 160
pyrrolidines - therapeutic use (158) 158
medicine & public health (157) 157
dosage and administration (155) 155
peptides (154) 154
randomized controlled trials as topic (154) 154
rats (154) 154
dpp-4 inhibitors (153) 153
peptidase (153) 153
health aspects (151) 151
nitriles - therapeutic use (151) 151
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (148) 148
cardiac & cardiovascular systems (146) 146
dipeptidyl-peptidase iv inhibitors (146) 146
hyperglycemia (146) 146
mice (146) 146
incretins - therapeutic use (144) 144
glp-1 (143) 143
drug-naive patients (142) 142
pharmacokinetics (138) 138
diabetes mellitus, type 2 - physiopathology (137) 137
time factors (137) 137
saxagliptin (132) 132
mortality (125) 125
glycosylated hemoglobin (124) 124
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2074) 2074
French (17) 17
German (15) 15
Spanish (15) 15
Japanese (7) 7
Hungarian (3) 3
Russian (3) 3
Czech (2) 2
Danish (1) 1
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 384 - 393
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | CLINICAL-TRIALS | VASCULAR OUTCOMES | RISK | COMPLICATIONS | THERAPIES | CARDIOVASCULAR SAFETY | MELLITUS | BLOOD-GLUCOSE CONTROL | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article